Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03441113




Registration number
NCT03441113
Ethics application status
Date submitted
15/02/2018
Date registered
22/02/2018
Date last updated
16/05/2024

Titles & IDs
Public title
Extended Access of Momelotinib in Adults With Myelofibrosis
Scientific title
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Secondary ID [1] 0 0
2017-004350-42
Secondary ID [2] 0 0
219627
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neoplasms 0 0
Post-polycythemia Vera Myelofibrosis (Post-PV MF) 0 0
Primary Myelofibrosis (PMF) 0 0
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MMB

Other: Cohort 1: Study GS-US-352-0101 - Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 until MMB receives regulatory approval and is commercially available, or development of the product ceases.

Other: Cohort 2: Study GS-US-352-1214 - Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 until MMB receives regulatory approval and is commercially available, or development of the product ceases.

Other: Cohort 3: Study GS-US-352-1154 - Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 until MMB receives regulatory approval and is commercially available, or development of the product ceases..

Other: Cohort 4: Study SRA-MMB-301 - Participants will continue to receive the same dosage regimen as in the previous MMB study SRA-MMB-301 until MMB receives regulatory approval and is commercially available, or development of the product ceases.


Treatment: Drugs: MMB
Tablet(s) administered orally once daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants Who Had Access to, and Received the Intervention
Timepoint [1] 0 0
Participants will be assessed every 12 weeks until discontinuation. Participation in this extended access study has been an average of approximately 8 months.

Eligibility
Key inclusion criteria
Key

- Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or
SRA-MMB-301

- Able to comprehend and willing to sign the informed consent form

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known hypersensitivity to MMB, its metabolites, or formulation excipients

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/05/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2026
Actual
Sample size
Target
Accrual to date
Final
237
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Icon Cancer Care Wesley - Hyde Park
Recruitment hospital [2] 0 0
GSK Investigational Site - South Brisbane
Recruitment hospital [3] 0 0
Flinders Medical Centre - Adelaide
Recruitment hospital [4] 0 0
GSK Investigational Site - Adelaide
Recruitment hospital [5] 0 0
GSK Investigational Site - Frankston
Recruitment hospital [6] 0 0
Frankston Hospital - Frankston
Recruitment hospital [7] 0 0
GSK Investigational Site - Melbourne
Recruitment hospital [8] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [9] 0 0
GSK Investigational Site - Parkville
Recruitment hospital [10] 0 0
Peter MacCallum Cancer Centre - Parkville
Recruitment hospital [11] 0 0
GSK Investigational Site - Perth
Recruitment hospital [12] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
4812 - Hyde Park
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
31 99 - Frankston
Recruitment postcode(s) [5] 0 0
3199 - Frankston
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment postcode(s) [7] 0 0
3050 - Parkville
Recruitment postcode(s) [8] 0 0
6000 - Perth
Recruitment postcode(s) [9] 0 0
6160 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Austria
State/province [15] 0 0
Upper Austria
Country [16] 0 0
Austria
State/province [16] 0 0
Vienna
Country [17] 0 0
Austria
State/province [17] 0 0
Linz
Country [18] 0 0
Austria
State/province [18] 0 0
Wien
Country [19] 0 0
Belgium
State/province [19] 0 0
West-Vlaanderen
Country [20] 0 0
Belgium
State/province [20] 0 0
Antwerpen
Country [21] 0 0
Belgium
State/province [21] 0 0
Antwerp
Country [22] 0 0
Belgium
State/province [22] 0 0
Brugge
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Belgium
State/province [24] 0 0
Liège
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Pleven
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Ruse
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Canada
State/province [29] 0 0
Quebec
Country [30] 0 0
Canada
State/province [30] 0 0
Montréal
Country [31] 0 0
Canada
State/province [31] 0 0
Toronto
Country [32] 0 0
Denmark
State/province [32] 0 0
Aalborg
Country [33] 0 0
Denmark
State/province [33] 0 0
Herlev
Country [34] 0 0
Denmark
State/province [34] 0 0
Koebenhavn
Country [35] 0 0
Denmark
State/province [35] 0 0
Ålborg
Country [36] 0 0
France
State/province [36] 0 0
ILE-De-FRANCE
Country [37] 0 0
France
State/province [37] 0 0
Pays De La Loire
Country [38] 0 0
France
State/province [38] 0 0
Le Mans Cedex
Country [39] 0 0
France
State/province [39] 0 0
Lille Cedex
Country [40] 0 0
France
State/province [40] 0 0
Marseille CEDEX 9
Country [41] 0 0
France
State/province [41] 0 0
Marseille
Country [42] 0 0
France
State/province [42] 0 0
Paris cedex 10
Country [43] 0 0
France
State/province [43] 0 0
Pessac cedex
Country [44] 0 0
France
State/province [44] 0 0
Pessac Cedex
Country [45] 0 0
France
State/province [45] 0 0
Pierre Bénite Cedex
Country [46] 0 0
France
State/province [46] 0 0
Pierre-Bénite cedex
Country [47] 0 0
France
State/province [47] 0 0
Toulouse Cedex 9
Country [48] 0 0
Germany
State/province [48] 0 0
Baden-Wuerttemberg
Country [49] 0 0
Germany
State/province [49] 0 0
Nordrhein-Westfalen
Country [50] 0 0
Germany
State/province [50] 0 0
Rheinland-Pfalz
Country [51] 0 0
Germany
State/province [51] 0 0
Sachsen-Anhalt
Country [52] 0 0
Germany
State/province [52] 0 0
Sachsen
Country [53] 0 0
Germany
State/province [53] 0 0
Schleswig-Holstein
Country [54] 0 0
Germany
State/province [54] 0 0
Cologne
Country [55] 0 0
Germany
State/province [55] 0 0
Dresden
Country [56] 0 0
Germany
State/province [56] 0 0
Leipzig
Country [57] 0 0
Germany
State/province [57] 0 0
Mainz
Country [58] 0 0
Hungary
State/province [58] 0 0
Gyor-Moson-Sopron
Country [59] 0 0
Hungary
State/province [59] 0 0
Komárom-Esztergom
Country [60] 0 0
Hungary
State/province [60] 0 0
Pest
Country [61] 0 0
Hungary
State/province [61] 0 0
Szabolcs-Szatmár-Bereg
Country [62] 0 0
Hungary
State/province [62] 0 0
Budapest
Country [63] 0 0
Hungary
State/province [63] 0 0
Debrecen
Country [64] 0 0
Hungary
State/province [64] 0 0
Gyor
Country [65] 0 0
Hungary
State/province [65] 0 0
Kaposvár
Country [66] 0 0
Hungary
State/province [66] 0 0
Nyiregyhaza
Country [67] 0 0
Hungary
State/province [67] 0 0
Tatabánya
Country [68] 0 0
Israel
State/province [68] 0 0
Afula
Country [69] 0 0
Israel
State/province [69] 0 0
Ashkelon
Country [70] 0 0
Israel
State/province [70] 0 0
Ashkelton
Country [71] 0 0
Israel
State/province [71] 0 0
Haifa
Country [72] 0 0
Israel
State/province [72] 0 0
Jerusalem
Country [73] 0 0
Israel
State/province [73] 0 0
Kfar Saba
Country [74] 0 0
Italy
State/province [74] 0 0
Basilicata
Country [75] 0 0
Italy
State/province [75] 0 0
Campania
Country [76] 0 0
Italy
State/province [76] 0 0
Emilia-Romagna
Country [77] 0 0
Italy
State/province [77] 0 0
Florence
Country [78] 0 0
Italy
State/province [78] 0 0
Liguria
Country [79] 0 0
Italy
State/province [79] 0 0
Lombardia
Country [80] 0 0
Italy
State/province [80] 0 0
Monza E Brianza
Country [81] 0 0
Italy
State/province [81] 0 0
Pesaro E Urbino
Country [82] 0 0
Italy
State/province [82] 0 0
Piemonte
Country [83] 0 0
Italy
State/province [83] 0 0
Toscana
Country [84] 0 0
Italy
State/province [84] 0 0
Trentino-Alto Adige
Country [85] 0 0
Italy
State/province [85] 0 0
Turin
Country [86] 0 0
Italy
State/province [86] 0 0
Veneto
Country [87] 0 0
Italy
State/province [87] 0 0
Bologna
Country [88] 0 0
Italy
State/province [88] 0 0
Genova
Country [89] 0 0
Italy
State/province [89] 0 0
Milano
Country [90] 0 0
Italy
State/province [90] 0 0
Napoli
Country [91] 0 0
Italy
State/province [91] 0 0
Pesaro
Country [92] 0 0
Italy
State/province [92] 0 0
Potenza
Country [93] 0 0
Italy
State/province [93] 0 0
Roma
Country [94] 0 0
Italy
State/province [94] 0 0
Verona
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Busan Gwang'yeogsi [Pusan-Kwangyokshi]
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Daegu Gwang'yeogsi
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Busan
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Daegu
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Seoul
Country [101] 0 0
Netherlands
State/province [101] 0 0
Limburg
Country [102] 0 0
Netherlands
State/province [102] 0 0
Maastricht
Country [103] 0 0
Poland
State/province [103] 0 0
Opolskie
Country [104] 0 0
Poland
State/province [104] 0 0
Podkarpacki
Country [105] 0 0
Poland
State/province [105] 0 0
Pomoskie
Country [106] 0 0
Poland
State/province [106] 0 0
Brzozow
Country [107] 0 0
Poland
State/province [107] 0 0
Chorzow
Country [108] 0 0
Poland
State/province [108] 0 0
Chorzów
Country [109] 0 0
Poland
State/province [109] 0 0
Gdansk
Country [110] 0 0
Poland
State/province [110] 0 0
Krakow
Country [111] 0 0
Poland
State/province [111] 0 0
Lublin
Country [112] 0 0
Poland
State/province [112] 0 0
Malogoskie
Country [113] 0 0
Poland
State/province [113] 0 0
Opole
Country [114] 0 0
Poland
State/province [114] 0 0
Poznan
Country [115] 0 0
Romania
State/province [115] 0 0
Brasov
Country [116] 0 0
Romania
State/province [116] 0 0
Bucharest
Country [117] 0 0
Romania
State/province [117] 0 0
Bucuresti
Country [118] 0 0
Romania
State/province [118] 0 0
Cluj-Napoca
Country [119] 0 0
Romania
State/province [119] 0 0
Craiova
Country [120] 0 0
Romania
State/province [120] 0 0
Iasi
Country [121] 0 0
Singapore
State/province [121] 0 0
Singapore
Country [122] 0 0
Spain
State/province [122] 0 0
Barcelona
Country [123] 0 0
Spain
State/province [123] 0 0
Madrid
Country [124] 0 0
Spain
State/province [124] 0 0
Majadahonda (Madrid)
Country [125] 0 0
Spain
State/province [125] 0 0
Pamplona
Country [126] 0 0
Spain
State/province [126] 0 0
Zaragoza
Country [127] 0 0
Taiwan
State/province [127] 0 0
Kaohsiung
Country [128] 0 0
Taiwan
State/province [128] 0 0
Taipei
Country [129] 0 0
Taiwan
State/province [129] 0 0
Taoyuan
Country [130] 0 0
United Kingdom
State/province [130] 0 0
England
Country [131] 0 0
United Kingdom
State/province [131] 0 0
Lanarkshire
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Scotland
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Bristol
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Cardiff
Country [135] 0 0
United Kingdom
State/province [135] 0 0
London
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Oxford.
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to provide extended access and assess long-term safety
of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia
vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies
GS-US-352-0101 (NCT01969838), GS-US-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746),
SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg
and 200 mg tablets) and have not experienced progression of disease. The secondary objective
is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03441113
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03441113